An assessment of current achievements in the systemic management of breast cancer

Marc E. Lippman

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Over the past twenty years, breast cancer has come to be much more commonly regarded and treated as a systemic disease. Conventional chemotherapy and endocrine therapy used according to schedules that are tolerable to patients are generally effective and often induce worthwhile responses; nevertheless, the responses in general have a median duration of less than a year, and these therapies are rarely if ever curative. Continued efforts to use available agents with mere modifications of schedule and intensity seem unlikely to substantially improve upon the modest success already achieved. Rather, we desperately need radically new schedules, new agents (especially non-myelosuppressive agents), and new approaches (e.g. monoclonal antibody targeting of drugs, toxins, or radionuclides, perhaps combined with tumor sensitizing agents such as heat). It is our hope that consideration of some of these issues will encourage others to be bolder in devising the next generation of clinical trials.

Original languageEnglish (US)
Pages (from-to)69-77
Number of pages9
JournalBreast cancer research and treatment
Issue number2
StatePublished - Jun 1 1984


  • breast cancer
  • chemotherapy
  • clinical trials
  • combined chemoendocrine therapy
  • immunotherapy
  • non-myelosuppressive agents
  • prognostic factors
  • response rates
  • targeting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'An assessment of current achievements in the systemic management of breast cancer'. Together they form a unique fingerprint.

Cite this